Full name

A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

NCT Number
NCT06041386
Geography
Non-US
Locations

[Location data not yet available]

Primary Endpoints

Percentage (%) of Participants Achieving 4-Component Clinical Remission At Month 12

Order
2
Disease
Menu title
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study (REIMAGINE)
Version
Phase
4